Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE011 (ITA) (Dr. Jansen)
· consented 2023-04-07
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 6); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-02 (study day 7); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Rash — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 22); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 33); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-04 (study day 40); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.